A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
about
Bridging academic science and clinical research in the search for novel targeted anti-cancer agentsMolecular pathology of cancer: how to communicate with diseaseStandardization and quality management in next-generation sequencingPrecision targeted therapy of ovarian cancerIdentification of a Tumor Specific, Active-Site Mutation in Casein Kinase 1α by Chemical ProteomicsMetabolic interrogation as a tool to optimize chemotherapeutic regimens.Validation of a Multiplexed Gene Signature Assay for Diagnosis of Canine Cancers from Formalin-Fixed Paraffin-Embedded TissuesDNA in serum extracellular vesicles is stable under different storage conditions.Molecular chess? Hallmarks of anti-cancer drug resistanceHepatocellular Carcinoma, Fibrolamellar Variant: Diagnostic Pathologic Criteria and Molecular Pathology Update. A Primer.DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance.Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation.Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significanceTissue-based next generation sequencing: application in a universal healthcare system.Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratoryA prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer.On the pharmacogenetics of non-small cell lung cancer treatment.Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?PI3K inhibitor enhances the cytotoxic response to etoposide and cisplatin in a newly established neuroendocrine cervical carcinoma cell line.New targeted therapies for malignant lymphoma based on molecular heterogeneity.Progress and prospects for the discovery of biomarkers for gastric cancer: a focus on proteomics.The Importance of Biopsy in the Era of Molecular Medicine.Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.The next generation of cancer management.Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison study.NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?Am I My Family's Keeper? Disclosure Dilemmas in Next-Generation Sequencing.Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients.Improving the CellSearch® system.Primary and Metastatic Melanoma With NTRK Fusions.NSCLC molecular testing in Central and Eastern European countries.
P2860
Q26771396-BFCD4FBB-2269-40C1-A6F5-7CE36814E823Q28076360-A073FA18-0D92-4C5C-90F8-F7E54E24947FQ28077041-AEA31B9A-4CF0-4335-B4AC-1592FC670C33Q28078658-E1CABECC-66C7-4459-ABD2-FE7F3B7E266EQ28551093-1E3C9958-A51A-470E-9020-21392DC35A2EQ33566853-5D25C0DE-1DFA-4004-956B-34B41D62B8B8Q33698804-027EFA02-B482-47DF-831F-A0734AB021F1Q36143293-636750DA-5655-4E76-B675-055DBA612DBAQ36240941-5FB0F6F6-6229-4A3B-9967-49C88CF0B5E0Q36731897-402CF730-FD50-40FE-AE0F-65BB8861ADF6Q37020946-2C7EDE56-330E-40B7-80D0-8E4936A5F80BQ37051546-AF5F5635-1C13-45ED-9D13-1F337122BAA9Q37286919-AF71458B-7CDE-4393-A8C4-DA9D760AF43DQ37327426-913CE7B6-CDA6-4494-B911-339234C2A0CFQ37457496-3F4DC354-0C81-47AD-8A39-BA13552389E1Q37691479-5346E66A-FBC6-4A3B-850A-BBBDCAF362CBQ38646681-CF15E90D-5C4D-476E-A490-036D52B70A9EQ38647048-E565B2A6-7E52-4313-9CA5-885E44C64EFCQ38694947-610D1706-8030-498F-B257-3C707EF0326BQ38697494-4D93B5CE-44B2-490E-B005-AEEF34A8546CQ38704263-F6AC5969-E0BE-463B-B520-7D4CBB9BC66DQ38787141-139367CA-7718-458C-BEB6-369C20AA6ABCQ38981782-39AE40AC-8293-4D72-B923-B04863D1E2CAQ39015512-842A0DBE-F2C1-45D9-80AF-67C4FBDFAA36Q39040207-2679C226-D13D-4982-A57A-F33BAB7F7215Q39163320-8204622E-B71C-4907-BB11-E5EF98EB2F49Q39187437-E356DFFB-79B9-48D5-8A3D-83082D491B48Q39294398-DE7B4F2B-CAE1-486C-8EAD-4DAA700D6626Q40784008-87E45046-CE18-4814-AF46-2D05D1E8E892Q42366577-3B365191-BDD1-4940-8378-767B50880D8CQ42695934-A9087D6B-767F-4152-B49A-64756564ABAEQ47391124-5E8E81AA-8C44-4E15-B400-9ED65866C2C1Q50057804-829C69DC-9FE7-40C1-A2F5-71D275CA948EQ51115531-0268ADE1-3285-4336-97E6-003150EFE6ACQ52570211-3139D87D-A95C-46F5-B9A3-75261D1F2977Q55284375-A85D5AEB-2310-4896-AB36-9ABAAE3AB51D
P2860
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A 2015 update on predictive mo ...... cussing on clinical relevance.
@en
type
label
A 2015 update on predictive mo ...... cussing on clinical relevance.
@en
prefLabel
A 2015 update on predictive mo ...... cussing on clinical relevance.
@en
P2093
P2860
P356
P1433
P1476
A 2015 update on predictive mo ...... cussing on clinical relevance.
@en
P2093
B M Pfitzner
F Klauschen
I Anagnostopoulos
P2860
P2888
P304
P356
10.1038/CGT.2015.39
P577
2015-09-11T00:00:00Z
P6179
1025569955